Fig. 34.2. Skin necrosis associated with an umbilical artery catheter. Such lesions develop after vasospasm or embolism. A: Spinal injury may be present when ischemia involves this region. B: The distal part

of an extremity is a common site for embolic arterial loss. The full extent of loss is unpredictable at this

stage. (From Fletcher MA. Physical Diagnosis in Neonatology. Philadelphia: Lippincott-Raven; 1998:127.)

Table 34.2 Laboratory Tests for Suspected Prothrombotic Disorders

Laboratory Test Collection Tube

Antiphospholipid antibody panel, anticardiolipin, lupus anticoagulant

(IgG, IgM)

Citrated plasma

Fibrinogen Citrated plasma

Protein C activity

Protein S activity

Antithrombin (activity assay)

Citrated plasma

Factor V Leiden

Prothrombin G

Methylenetetrahydrofolate reductase

Ethylenediaminetetraacetic acid

Homocysteine

Lipoprotein(a)

Citrated plasma

From Saxonhouse MA. Management of neonatal thrombosis. Clin Perinatol. 2012;39:191,with permission.


Chapter 34 ■ Management of Vascular Spasm and Thrombosis 227

c. Anticoagulation for at least 10 days; UFH or LMWH

is recommended for neonates with UAC-related

thrombosis.

d. If there are potentially life-, limb-, or organ-threatening signs in neonates with UAC-related thrombosis,

thrombolysis with rTPA should be considered.

e. If there are contraindications to thrombolysis, surgical thrombectomy may be indicated.

4. Anticoagulant/thrombolytic therapy

a. Contraindications

(1) Major surgery within the last 10 days

(2) Active or major bleeding: Intracranial, pulmonary, or gastrointestinal

(3) Preexisting cerebral ischemic lesions

(4) Seizures within 48 hours

(5) Relative contraindications (anticoagulant/

thrombolytic therapy may be given after correction of these abnormalities)

(a) Thrombocytopenia (platelet count <100 ×

109

/L)

(b) Hypofibrinogenemia (fibrinogen <100 mg/

dL)

(c) Severe coagulation factor deficiency

(d) Hypertension

b. Precautions

(1) No arterial punctures

(2) No subcutaneous or intramuscular injections

(3) No urinary catheterizations

(4) Avoid aspirin or other antiplatelet drugs.

(5) Monitor serial head ultrasound scans for intracranial hemorrhage.

c. Anticoagulants

(1) UFH

(a) Anticoagulant, antithrombotic effect limited by low plasma levels of antithrombin in

neonates.

Comments

Search This Blog

Archive

Show more

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

علاقة البيبي بالفراولة بالالفا فيتو بروتين

التغيرات الخمس التي تحدث للجسم عند المشي

إحصائيات سنة 2020 | تعداد سكَان دول إفريقيا تنازليا :

ما هو الليمونير للأسنان ؟

ACUPAN 20 MG, Solution injectable

CELEPHI 200 MG, Gélule

الام الظهر

VOXCIB 200 MG, Gélule

ميبستان

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

Popular posts from this blog

TRIPASS XR تري باس

CELEPHI 200 MG, Gélule

ZENOXIA 15 MG, Comprimé

VOXCIB 200 MG, Gélule

Kana Brax Laberax

فومي كايند

بعض الادويه نجد رموز عليها مثل IR ، MR, XR, CR, SR , DS ماذا تعني هذه الرموز

NIFLURIL 700 MG, Suppositoire adulte

Antifongiques مضادات الفطريات

Popular posts from this blog

Kana Brax Laberax

TRIPASS XR تري باس

PARANTAL 100 MG, Suppositoire بارانتال 100 مجم تحاميل

الكبد الدهني Fatty Liver

الم اسفل الظهر (الحاد) الذي يظهر بشكل مفاجئ bal-agrisi

SEDALGIC 37.5 MG / 325 MG, Comprimé pelliculé [P] سيدالجيك 37.5 مجم / 325 مجم ، قرص مغلف [P]

نمـو الدمـاغ والتطـور العقـلي لـدى الطفـل

CELEPHI 200 MG, Gélule

أخطر أنواع المخدرات فى العالم و الشرق الاوسط

Archive

Show more